Speciality
Spotlight

       




 

Medicine

   

 




Drug
Evaluation

   

  • Lowe 
    M.N. & Lamb H.M.

    Meropenem
    – An updated Review of its use in the Management of
    Intra-Abdominal Infections

    Drugs,
    Sept 2000; 60 : 619-646

      

    Meropenem
    is a carbapenem antibacterial agent with a broad
    spectrum of activity which encompasses Gram
    negative, Gram positive and anaerobic bacteria. It
    is resistant to beta lactamases.

     

    In
    patients with moderate to severe intra-abdominal
    infections, empirical monotherapy with meropenem
    achieved clinical response rates ranging from 91% to
    100% in 7 randomised comparative trials.

          

  • Early Inhaled Glucocorticoid Therapy to Prevent Bronchopulmonary Dysplasia

    Cole CH, Colton T, Shah BL, et al (Tufts Univ, Boston; Boston Univ; Pensylvania Hosp, Philadelphia)

    N Engl J Med 340: 1005- 1010, 1999

       

    Bronchopulmonary dysplasia (BPD) is a disease seen in premature babies. Inflammatory mediator cytokine plays a key role in its development following prenatal or postnatal sepsis. The current treatment for BPD is the use of systemic steroids and mechanical ventilation.

       

    The present study evaluated the role of inhaled beclomethasone in neonates with BPD. The study concluded that early therapy with inhaled beclomethasone did not significantly alter the incidence of BPD at 28 days of age or at 36 weeks of gestational age. However with the use of inhaled beclomethasone requirement for systemic glucocorticoids and bronchodilator therapy decreased significantly. Also at 28 days, fewer patients receiving inhaled beclomethasone still required mechanical ventilation.

        

    Thus inhaled steroids started in the first 2 weeks of life does not prevent BPD but like systemic steroids, does reduce the need for & duration of mechanical ventilation.

           

 



 

           

Speciality Spotlight

       

 
Medicine
   

 

Drug Evaluation
   

  • Lowe  M.N. & Lamb H.M.
    Meropenem – An updated Review of its use in the Management of Intra-Abdominal Infections
    Drugs, Sept 2000; 60 : 619-646
      
    Meropenem is a carbapenem antibacterial agent with a broad spectrum of activity which encompasses Gram negative, Gram positive and anaerobic bacteria. It is resistant to beta lactamases.
     
    In patients with moderate to severe intra-abdominal infections, empirical monotherapy with meropenem achieved clinical response rates ranging from 91% to 100% in 7 randomised comparative trials.
          

  • Early Inhaled Glucocorticoid Therapy to Prevent Bronchopulmonary Dysplasia
    Cole CH, Colton T, Shah BL, et al (Tufts Univ, Boston; Boston Univ; Pensylvania Hosp, Philadelphia)
    N Engl J Med 340: 1005- 1010, 1999
       
    Bronchopulmonary dysplasia (BPD) is a disease seen in premature babies. Inflammatory mediator cytokine plays a key role in its development following prenatal or postnatal sepsis. The current treatment for BPD is the use of systemic steroids and mechanical ventilation.
       
    The present study evaluated the role of inhaled beclomethasone in neonates with BPD. The study concluded that early therapy with inhaled beclomethasone did not significantly alter the incidence of BPD at 28 days of age or at 36 weeks of gestational age. However with the use of inhaled beclomethasone requirement for systemic glucocorticoids and bronchodilator therapy decreased significantly. Also at 28 days, fewer patients receiving inhaled beclomethasone still required mechanical ventilation.
        
    Thus inhaled steroids started in the first 2 weeks of life does not prevent BPD but like systemic steroids, does reduce the need for & duration of mechanical ventilation.
           

 

 

By |2022-07-20T16:42:04+00:00July 20, 2022|Uncategorized|Comments Off on Drug Evaluation

About the Author: